D-Ribose for Fatigue in Subjects With Fibromyalgia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01315210
Recruitment Status : Completed
First Posted : March 15, 2011
Last Update Posted : September 18, 2013
Information provided by (Responsible Party):
RiboCor, Inc.

Brief Summary:
To evaluate the safety and to determine the efficacy of D-ribose for the amelioration of fatigue in subjects with fibromyalgia. This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center, multiple dose study of D-ribose versus placebo administered at doses of 5 g three times a day (TID) over a 12-week period to subjects who are experiencing fatigue associated with a diagnosis of fibromyalgia.

Condition or disease Intervention/treatment Phase
Fibromyalgia Drug: D-Ribose Powder Dietary Supplement: Placebo Powder Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 110 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of D-Ribose in Subjects With Fibromyalgia
Study Start Date : May 2011
Actual Primary Completion Date : October 2012
Actual Study Completion Date : October 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fatigue Fibromyalgia

Arm Intervention/treatment
Experimental: D-Ribose Drug: D-Ribose Powder
5 g TID for 12 Weeks

Placebo Comparator: Placebo Dietary Supplement: Placebo Powder
5 g TID for 12 Weeks

Primary Outcome Measures :
  1. Subject's Assessment of Fatigue (NRS) [ Time Frame: 12 Weeks ]

Secondary Outcome Measures :
  1. Revised Fibromyalgia Impact Questionnaire [ Time Frame: 12 Weeks ]
  2. Multidimensional Fatigue Inventory [ Time Frame: 12 Weeks ]
  3. Subject's Global Impression of Change [ Time Frame: 12 Weeks ]
  4. SF-36 [ Time Frame: 12 Weeks ]
  5. Subject's Assessment of Pain Intensity (NRS) [ Time Frame: 12 Weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Major Inclusion Criteria:

  • must have a diagnosis of primary fibromyalgia, as defined by the 1990 American College of Rheumatology (ACR) Criteria for the Classification of Fibromyalgia made at least 6 weeks prior to the Pretreatment Screening Visit;
  • must have a score of ≥5 on the Subject's Assessment of Fatigue 11-point numerical rating scale (NRS) at the Pretreatment Screening and Baseline Visits;
  • if taking acetaminophen or other non-opioid analgesics, NSAIDs, fibromyalgia medications, medications to induce sleep, or prednisone ≤ 10 mg (or equivalent dose of other glucocorticoids), must be on stable dose(s) for at least 4 weeks prior to the baseline visit;
  • must have discontinued any ribose-containing products (including foods, drinks, and supplements) at least 4 weeks prior to the Pretreatment Baseline Visit.

Major Exclusion Criteria:

  • current major depressive episode (MDE);
  • has been diagnosed with any autoimmune disease;
  • has been diagnosed with type I or type II diabetes;
  • has a history of cancer, other than basal cell carcinoma, stage 1 squamous cell carcinoma or cervical carcinoma in situ, that has not been in remission for at least five years prior to the Pretreatment Screening Visit;
  • has been diagnosed with chronic fatigue syndrome.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01315210

United States, California
Superior Research, LLC
Sacramento, California, United States, 95825
United States, Florida
Avail Clinical Research
Deland, Florida, United States, 32720
Renstar Medical Research
Ocala, Florida, United States, 34471
United States, Kentucky
University of Kentucky
Lexington, Kentucky, United States, 40536
United States, Maryland
Columbia Medical Practice
Columbia, Maryland, United States, 21045
The Center for Rheumatology and Bone Research
Wheaton, Maryland, United States, 20902
United States, North Carolina
Peters Medical Research
High Point, North Carolina, United States, 27262
Wake Research Associates, LLC
Raleigh, North Carolina, United States, 27612
United States, Pennsylvania
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States, 16635
Sponsors and Collaborators
RiboCor, Inc.
Principal Investigator: Leslie Crofford, MD University of Kentucky

Responsible Party: RiboCor, Inc. Identifier: NCT01315210     History of Changes
Other Study ID Numbers: BIOE 02C 010
First Posted: March 15, 2011    Key Record Dates
Last Update Posted: September 18, 2013
Last Verified: September 2013

Keywords provided by RiboCor, Inc.:

Additional relevant MeSH terms:
Myofascial Pain Syndromes
Muscular Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Neuromuscular Diseases
Nervous System Diseases